Tags: Allergies | sinusitis | dupilumab | treatment | relief | drug

Chronic Sinusitis: New Drug Shows Promise

Tuesday, 30 Sep 2014 09:10 AM

An experimental drug from Sanofi and Regeneron significantly reduced congestion in in a mid-stage trial on patients with chronic sinusitis with nasal polyps, a condition poorly controlled by existing drugs, the companies said on Tuesday.
 
In a Phase IIa trial of dupilumab in patients who did not respond to intranasal corticosteroids, the injectable drug brought a statistically significant reduction in the size of nasal polyps and improved other symptoms such as congestion and sleep disruption, Sanofi said.

Dupilumab is also being tested by the drugmakers against two other allergic conditions - atopic dermatitis and asthma.

The drug was named "clinical advance of the year" in 2013 by industry publication Scrip Intelligence, and some analysts say it could capture annual sales of up to $2 billion if approved.

Chronic sinusitis with nasal polyps causes inflammation of the mucosa and polyps in the nasal cavity and sinuses, resulting in congestion, a reduced sense of smell and facial pain.

Patients gain limited relief from intranasal corticosteroids, the only therapy currently available. Dupilumab works through a new approach, by blocking two proteins linked to inflammation, interleukin-4 (IL-4) and interleukin-13 (IL-13)

Sanofi said the findings of the trial on 60 adults with moderate-to-severe disease, combined with previous encouraging Phase II data for dupilumab in asthma and atopic dermatitis, supported evidence that these conditions may result from a core allergic inflammatory process driven by the IL-4/IL-13 pathway.

About 30 percent of patients with chronic sinusitis with nasal polyps also have asthma, and in an exploratory analysis, dupilumab-treated patients with both conditions also experienced significant improvement in asthma control, Sanofi noted.

The drug's main side effects were injection site reactions, common cold, sore throat, nosebleed, headache and dizziness.

Sanofi said it would present detailed results of the study at a medical conference and pursue further clinical trials.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Health-News
An experimental drug from Sanofi and Regeneron significantly reduced congestion in in amid-stage trial on patients with chronic sinusitis with nasal polyps, a condition poorly controlled by existing drugs, the companies said on Tuesday. In a Phase II a trial of dupilumab in...
sinusitis, dupilumab, treatment, relief, drug
300
2014-10-30
Tuesday, 30 Sep 2014 09:10 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved